Grammatopoulos Dimitris K
Translational Medicine, Warwick Medical School & Clinical Biochemistry, Coventry and Warwickshire Pathology Service, United Kingdom.
Mol Cell Endocrinol. 2017 Jul 5;449:82-89. doi: 10.1016/j.mce.2017.02.013. Epub 2017 Feb 14.
G-protein coupled receptors (GPCRs) have long been at the center of investigations of the neurobiology of depression and mood disorders. Different facets of GPCR signalling pathways, including those controlling monoaminergic and neuropeptidergic hormonal systems are believed to be dysregulated in major depressive and bipolar disorders. Although these receptors are key molecular targets for a variety of therapeutic agents and continue to be the focus of intense pharmaceutical development, the molecular mechanisms activated by these GPCRs and underpin the pathological basis of mood disorders remain poorly understood. This review will discuss some of the emerging regulatory mechanisms of GPCR signaling in the central nervous system (CNS) involving protein-protein interactions, downstream effectors and cross-talk with other signaling molecules and their potential involvement in the neurobiology of psychiatric disease.
G蛋白偶联受体(GPCRs)长期以来一直是抑郁症和情绪障碍神经生物学研究的核心。GPCR信号通路的不同方面,包括那些控制单胺能和神经肽能激素系统的方面,被认为在重度抑郁症和双相情感障碍中失调。尽管这些受体是多种治疗药物的关键分子靶点,并且仍然是药物研发的重点,但这些GPCRs激活的分子机制以及构成情绪障碍病理基础的机制仍知之甚少。本综述将讨论中枢神经系统(CNS)中GPCR信号传导的一些新兴调节机制,包括蛋白质-蛋白质相互作用、下游效应器以及与其他信号分子的相互作用,以及它们在精神疾病神经生物学中的潜在作用。